Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223

Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherji, Deborah, El Dika, Imane, Temraz, Sally, Haidar, Mohammed, Shamseddine, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043797/
https://www.ncbi.nlm.nih.gov/pubmed/24920911
http://dx.doi.org/10.2147/TCRM.S45667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043797/
https://www.ncbi.nlm.nih.gov/pubmed/24920911
http://dx.doi.org/10.2147/TCRM.S45667

Ejemplares similares